The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer

Abstract The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway plays a critical role in the malignant transformation of human tumors and their subsequent growth, proliferation, and metastasis. Preclinical investigations have suggested that the PI3K/AKT/mTOR pathwa...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2015-04, Vol.137 (1), p.173-179
Main Authors: Mabuchi, Seiji, Kuroda, Hiromasa, Takahashi, Ryoko, Sasano, Tomoyuki
Format: Article
Language:English
Subjects:
AKT
Animals
Female
Hematology, Oncology and Palliative Medicine
Humans
Molecular Targeted Therapy
mTOR
mTORC1
mTORC2
Obstetrics and Gynecology
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - metabolism
Phosphatidylinositol 3-Kinases - antagonists & inhibitors
Phosphatidylinositol 3-Kinases - genetics
Phosphatidylinositol 3-Kinases - metabolism
PI3K
Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Proto-Oncogene Proteins c-akt - genetics
Proto-Oncogene Proteins c-akt - metabolism
Signal Transduction - drug effects
TOR Serine-Threonine Kinases - antagonists & inhibitors
TOR Serine-Threonine Kinases - genetics
TOR Serine-Threonine Kinases - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway plays a critical role in the malignant transformation of human tumors and their subsequent growth, proliferation, and metastasis. Preclinical investigations have suggested that the PI3K/AKT/mTOR pathway is frequently activated in ovarian cancer, especially in clear cell carcinoma and endometrioid adenocarcinoma. Thus, this pathway is regarded as an attractive candidate for therapeutic interventions, and inhibitors targeting different components of this pathway are in various stages of clinical development. Here, we highlight the recent progress that has been made in our understanding of the PI3K/AKT/mTOR pathway and discuss the potential of therapeutic agents that target this pathway as treatments for ovarian cancer and the obstacles to their development.
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2015.02.003